IAS 2025 conference now open access
21 September 2025. Related: Conference reports, On the web.
IAS 13th Kigali 2025
IAS 2025: Limited access to CD4 tests misses late diagnoses and advanced HIV disease (AHD)
8 August 2025. Related: Conference reports, Treatment strategies, Guidelines, Coinfections and complications.
IAS 2025: Induced stress can increase HIV dynamics
7 August 2025. Related: Conference reports, Cure-related research, Basic science and immunology.
Featured IAS 2025: WHO guidelines: major updates on injectables, AHD, breastfeeding, infant prophylaxis and peer support
2 August 2025. Related: Conference reports, Guidelines.
13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports
31 July 2025. Related: Conference reports, Activism & advocacy.
IAS 2025: The Kigali Manifesto on the inclusion of people living with HIV in clinical research
31 July 2025. Related: Conference reports, Treatment access, Coinfections and complications, Cancer and HIV, Activism & advocacy, Research studies.
IAS 2025: Switching to injectable CAB/RPV-LA with detectable viral load: results from the OPERA cohort
28 July 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
IAS 2025: Switching to dual ART after durable suppression on triple-drug ART in West and Central Africa
27 July 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
IAS 2025: Increases in reports of HIV criminalisation cases globally
26 July 2025. Related: Conference reports, Activism & advocacy.
IAS 2025: Once-weekly oral ART with ulonivirine plus islatravir: 24-week phase 2 results
20 July 2025. Related: Conference reports, Antiretrovirals.
IAS 2025: Reduced dosing could be a safe option for adults: crisis response to ART stock-outs
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: 5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no differences in clinical outcomes
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks
17 July 2025. Related: Conference reports, Antiretrovirals, Drug resistance.
IAS 2025: Once-monthly oral PrEP using MK-8527: the drug that could stop HIV
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: “We will not be erased” – a community Call to Action
15 July 2025. Related: Conference reports, Treatment access, Activism & advocacy.
IAS 2025: HIV care is political: early focus on the funding crisis
12 July 2025. Related: Conference reports, Treatment access.
IAS 2025: HIV cure research at IAS 2025
12 July 2025. Related: Conference reports.
IAS 2025: Kigali Call to Action: sign-on to global leaders
1 July 2025. Related: Conference reports.